Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 15:3:100063.
doi: 10.1016/j.prdoa.2020.100063. eCollection 2020.

Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice

Richard M Trosch  1 , Vijay P Misra  2 , Pascal Maisonobe  3 , Savary Om  3
Affiliations

Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice

Richard M Trosch et al. Clin Park Relat Disord. .

Abstract

Introduction: The efficacy and safety of abobotulinumtoxinA in the management of cervical dystonia has been established in randomized, controlled trials that use a selected trial population. In this meta-analysis of observational data, we evaluated the real-life effectiveness of abobotulinumtoxinA as delivered in routine clinical practice.

Methods: Meta-analysis of patient-level data for adult patients with cervical dystonia treated with abobotulinumtoxinA from three prospective, multicenter, observational studies (NCT01314365, NCT00833196 and NCT01753349).

Results: We report data for patients treated with abobotulinumtoxinA over one injection cycle at 181 neurology centers in 35 countries. CD clinical features as assessed by Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total scores (N = 920) significantly reduced by a mean [95%CI] of -12.9 [-13.9, -11.8] points at Week 4 (N = 449) and -3.2 [-3.8, -2.7] points at the end of the injection cycle (N = 890). All three TWSTRS domains (symptom severity, disability and pain) contributed to the overall improvement. Patients were generally content with symptom control at peak effect of the treatment cycle, with 86% reporting overall satisfaction.

Conclusion: Findings from this meta-analysis of observational studies confirm the effectiveness of abobotulinumtoxinA in routine practice. Despite inclusion of a broader population sample, the magnitude of improvements observed is consistent with that seen in the pivotal, randomized controlled trials.

Keywords: Botulinum toxin; Cervical dystonia; Meta-analysis; Observational study.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean change from baseline in TWSTRS scores, at peak effect (Week 4) and end of cycle. TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale. Data for Week 4 are based on INTEREST IN CD1 and ANCHOR, data for end of cycle are from all three studies.
See this image and copyright information in PMC

References

    1. Albanese A., Bhatia K., Bressman S.B., Delong M.R., Fahn S., Fung V.S., Hallett M., Jankovic J., Jinnah H.A., Klein C., Lang A.E., Mink J.W., Teller J.K. Phenomenology and classification of dystonia: a consensus update. Mov. Disord. 2013;28(7):863–873. - PMC - PubMed
    1. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5:864–872. - PubMed
    1. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., Kessler K.R., Ceballos-Baumann A.O., Ohly A., Oertel W., Kunig G. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport German Dystonia Study Group. J. Neurol. Neurosurg. Psychiatry. 1998;64:13–17. - PMC - PubMed
    1. Wissel J., Kanovsky P., Ruzicka E., Bares M., Hortova H., Streitova H., Jech R., Roth J., Brenneis C., Muller J., Schnider P., Auff E., Richardson A., Poewe W. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J. Neurol. 2001;248:1073–1078. - PubMed
    1. Truong D., Brodsky M., Lew M., Brashear A., Jankovic J., Molho E., Orlova O., Timerbaeva S., Global Dysport Cervical Dystonia Study G Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat. Disord. 2010;16:316–323. - PubMed

Associated data